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ABSTRACT
Epidemiological and experimental data suggest that both robust neutralizing antibodies and potent cellular
responses play important roles in controlling primary HIV-1 infection. In this study we have investigated the
induction of systemic and mucosal immune responses to HIV gp120 monomer immunogen administered in-
tranasally in a novel, oil-in-water nanoemulsion (NE) adjuvant. Mice and guinea pigs intranasally immunized
by the application of recombinant HIV gp120 antigen mixed in NE demonstrated robust serum anti-gp120
IgG, as well as bronchial, vaginal, and serum anti-gp120 IgA in mice. The serum of these animals demon-
strated antibodies that cross-reacted with heterologous serotypes of gp120 and had significant neutralizing
activity against two clade-B laboratory strains of HIV (HIVBaL and HIVSF162) and five primary HIV-1 iso-
lates. The analysis of gp120-specific CTL proliferation, INF- induction, and prevalence of anti-gp120 IgG2
subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular im-




THE UNIQUE IMMUNOBIOLOGY OF HIV, the diversity of virusisolates, variables in the immunogenicity of viral antigens,
and the lack of clear correlates of protection with specific as-
pects of anti-HIV immunity have all raised fundamental ques-
tions about the potential for protective HIV vaccination.1–3 De-
spite this, multiple approaches for the development of a vaccine
to prevent HIV infection or control virus-associated disease
have been attempted. The HIV envelope glycoprotein (Env) is
a major target for neutralizing antibodies.4 Because of its cen-
tral role in mediating virus binding to cellular CD4 and facili-
tating coreceptor interaction, the gp120 component of Env, in
both monomeric and native oligomeric forms, has been used as
a principal HIV vaccine immunogen.5,6 Unfortunately, initial
attempts to employ gp120 as a traditional vaccine immunogen
failed.7–9 Because epidemiological and immunological evi-
dence suggests that an effective HIV vaccine will need to elicit
both virus-specific neutralizing antibodies and cytotoxic T cell
responses against HIV-1,10–16 recent HIV vaccines explored
various combinations of viral and/or DNA vectors and recom-
binant Env proteins.3,17–21 While some of these approaches may
work, many are complex and it is clear new approaches are still
needed.22–24
Primary HIV-1 infection typically occurs via mucosal sur-
faces turning attention to vaccines that could induce anti-HIV
mucosal immunity. Intranasal immunizations have been re-
ported to induce both mucosal and systemic immune re-
sponses.19,25,26 Several experimental and commercial human
nasal vaccines for mucosally transmitted viral and bacterial
pathogens have been pursued in recent years.27–30 In contrast,
initial candidate HIV vaccines have predominantly used tradi-
tional human adjuvants not associated with mucosal immunity
and have been administered by subcutaneous injection.3,14 A
few recent HIV vaccine approaches have attempted mucosal
immunization through multiple strategies, including inactivated
HIV-1,31,32 live-attenuated viral vectors,33,34 bacterial vec-
tors,35,36 virus-like particles (VLPs),37 naked DNA,38,39 toxins,
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and cytokines.40–42 However, both safety concerns regarding
attenuated pathogens and side effects from mucosal bacterial
toxin-containing adjuvants have limited the use of these ap-
proaches for human mucosal vaccines.43–45 Therefore, the lack
of safe and effective mucosal adjuvants capable of eliciting both
neutralizing antibodies and cytotoxic T lymphocyte (CTL)-me-
diated responses limits development of mucosal vaccines, es-
pecially for HIV.46–48
The current studies evaluate an oil-in-water nanoemulsion
(NE) as a mucosal adjuvant for a recombinant gp120 HIV vac-
cine. Previous studies have demonstrated that NEs have broad
antimicrobial activity49,50 and are safe and effective nonin-
flammatory mucosal adjuvants for influenza and recombinant
anthrax protective antigen vaccines.51,52 In the present work,
the nanoemulsion was simply mixed with recombinant gp120
and applied to the nares of mice and guinea pigs. We then as-
sessed the induction of both mucosal and systemic anti-gp120
antibodies and the cross-reactivity of these antibodies with dif-
ferent gp120 serotypes, and also evaluated the animal’s sera for
HIV neutralization activity. In addition, we characterized the
systemic gp120-specific cellular response induced by mucosal
immunization with NE adjuvant. Our results suggest that this




Pathogen-free, female BALB/c mice (5–6 weeks old) and
Hartley guinea pigs (females, 250 g) were purchased from
Charles River Laboratories (Wilmington, MA). The mice and
guinea pigs were cared for in accordance with the American
Association for Accreditation of Laboratory Animal Care stan-
dards. All procedures involving animals were approved by the
University Committee on Use and Care of Animals (UCUCA)
at the University of Michigan.
Reagents
Recombinant HIV gp120BaL and gp120SF162 serotype pro-
teins produced in yeast were obtained from Quantum Biologi-
cal, Inc., through The NIAID Vaccine Research Resource. The
5 mg/ml aliquots of the protein solutions in a sterile saline were
stored at 80°C until used. The synthetic V3 loop peptide
(BaL) was obtained as a gift from Dr. Steven King (University
of Michigan). The 20-mer oligonucleotide (ODN) 5-TCC ATG
ACG TTC CGT ACG TT -3,53 containing nonmethylated CpG
repeats, was synthesized by Integrated DNA Technologies
(IDT, Coralville, IA). The Salmonella minnesota monophos-
phoryl lipid A (MPL A, #L-6638), phytohemagglutinin protein
(PHA-P), bovine serum albumin (BSA), dithiothreitol (DTT),
and other chemicals used in buffers were purchased from
Sigma-Aldrich Corporation (St. Louis, MO). The saline solu-
tion, phosphate-buffered saline (PBS), cell culture media, and
fetal bovine serum (FBS) were purchased from GIBCO (Grand
Island, NY) and HyClone (Logan, UT), respectively. The al-
kaline phosphatase (AP)-conjugated antibodies, goat antimouse
IgG, and goat antimouse IgA ( chain specific) were purchased
from Sigma. The secondary antibodies, AP conjugates rabbit
antimouse IgG1, IgG2a, IgG2b, and IgG3 and rabbit anti-guinea
pig IgG, were bought from Rockland Immunochemicals, Inc.
Preparation of the gp120/adjuvant formulations
The oil-in-water NE used in these studies was supplied by
NanoBio Corporation (Ann Arbor, MI). NE was produced by
the emulsification of cetylpyridinium chloride (CPC, 1%), a
nonionic surfactant (5%), and ethanol (8%) in water with hot-
pressed soybean oil (64%), using a high-speed emulsifier.49 Ex-
cept for the CPC, this nanoemulsion is formulated with surfac-
tant and food substances considered “Generally Recognized as
Safe” (GRAS) by the Food and Drug Administration (FDA).
NE mean droplet size (approximately 350 nm in diameter) was
determined by dynamic light scattering (DLS) using the
NICOMP 380 ZLS (PSS NICOMP Particle Sizing Systems,
Santa Barbara, CA).
All gp120/NE formulations were prepared by mixing gp120
protein solution with NE, using pyrogen-free saline as a dilu-
ent. Murine immunization studies were performed with a 20 g
dose of gp120 mixed with 0.1%, 0.5%, and 1% NE concentra-
tions. For immunization with additional immunostimulants, ei-
ther 5 g of MPL A or 10 g CpG ODN was added to 20 g
gp120 in 1% NE or to 20 g gp120 in saline. A guinea pig im-
munization study was performed using a 50 g dose of gp120
mixed with 1% NE and normal saline as diluent.
Immunization procedures
BALB/c mice (five animals per group) were immunized with
two, and on one occasion with three, intranasal administrations
of gp120/NE formulation at 3 weeks apart. The immunizations
were performed by slowly applying gp120/NE mixes (10 l per
nare) to the nares of isoflurane-anesthetized mice. During ad-
ministration, animals were held in the inverted position until
the droplets were completely inhaled. Control mice were im-
munized with gp120 in saline, with NE alone or saline. Intra-
muscular immunization was performed with two doses, 3 weeks
apart, of 20 g gp120 injected in 50 l of either saline or 1%
NE. Hartley guinea pigs (three animals per group) were anes-
thetized with the ketamine injection (40 mg/kg) and immunized
intranasally with two intranasal administrations of gp120/NE
mix (50 l per nare) at 3 weeks apart.
Collection of blood, bronchial alveolar lavage, vaginal
washes, and splenocytes
Blood samples were obtained before and 3 weeks after final
immunizations either from the saphenous vein, at various time
points during the course of the experiment, or by cardiac punc-
ture from euthanized premorbid mice. Serum was obtained from
coagulated blood (30–60 min at room temperature) by cen-
trifugation at 1500  g for 5 min. Collected serum samples
were heat inactivated at 56°C for 1 h and stored at 20°C un-
til analyzed.
Mouse bronchial alveolar lavage (BAL) fluid was obtained
from animals euthanized by inhalation of isoflurane. The lung
was infused twice with 0.5 ml of PBS with 10 M DTT and
0.5 mg/ml aprotinin and approximately 1 ml of aspirate was re-
covered. BAL samples were stored at 20°C until analyzed.
Vaginal wash samples were collected from anesthetized mice
BIELINSKA ET AL.272
by infusion of vaginal cavities with 100 l of PBS with 10 M
DTT and 0.5 mg/ml aprotinin. The samples were centrifugated
at 10,000  g for 5 min at 4°C, and the supernatants were stored
at 20°C until analyzed.
Murine splenocytes were mechanically isolated to obtain sin-
gle cell suspension in PBS. The red blood cells (RBC) were re-
moved by lysis with ACK buffer (150 mM NH4Cl, 10 mM
KHCO3, 0.1 mM Na2EDTA), and the remaining cells were
washed twice in PBS. For the antigen-specific proliferation or
cytokine expression assays, splenocytes (2–4  106 cells/ml)
were resuspended in RPMI 1640 medium, supplemented with
2% FBS, L-glutamine, and penicillin/streptomycin (100 U/ml
and 100 g/ml).
Determination of anti-gp120 IgG and IgA antibodies
Mouse anti-gp120-specific IgG and IgA levels were deter-
mined by enzyme-linked immunosorbent assay (ELISA). Mi-
crotiter plates (MaxiSorp; Nalge Nunc International, Roches-
ter, NY) were coated with 5 g/ml (100 l) of either gp120BaL
or gp120SF162 serotype envelope protein in the coating buffer
(50 mM sodium carbonate, 50 mM sodium bicarbonate, pH 9.6)
and incubated overnight at 4°C. After the protein solution was
removed, plates were blocked for 30 min at 37°C with PBS–1%
dry milk solution. The blocking solution was aspirated and
plates were used immediately or stored sealed at 4°C until
needed. Serum and BAL samples were serially diluted in 0.1%
BSA in PBS, and 100 l/well aliquots were incubated in gp120-
coated plates for 1 h at 37°C. The plates were washed three
times with PBS–0.05% Tween 20, followed by 1 h incubation
with either antimouse IgG or antimouse IgA AP-conjugated 
antibodies, then washed three times and incubated with AP 
substrate SigmaFast (Sigma, St. Louis, MO) according to the
manufacturer’s protocol. Spectrophotometric readouts were
performed using the Spectra Max 340 ELISA reader (Molecu-
lar Devices, Sunnyvale, CA) at 405 nm and reference wave-
length of 690 nm. Endpoint antibody titers were defined as the
last reciprocal serial serum dilution at which the absorption at
405 nm was greater than two times absorbance above negative
control. Guinea pig anti-gp120 IgG was determined by the same
method, except that rabbit anti-guinea pig IgG AP conjugate
(Rockland) was used for detection. Antibody concentrations are
presented as the mean  standard deviation (SD) of endpoint
titers.
HIV-1 single-round neutralization assay
The panel of eight strains of clade B HIV-1 used in this study
consists of the laboratory strains BaL, SF162, and MN, and pri-
mary HIV-1 isolates SS1196.11, BG1168.1, QH0692.42,
3988.25, and 5768.04.54 Virus neutralization was measured as
a function of the reductions in luciferase reporter gene expres-
sion after a single round of virus infection in TZM-bl cells as
described previously.55 The TZM-bl cells are engineered to ex-
press CD4 and CCR5 and contain integrated reporter genes for
firefly luciferase and Escherichia coli -galactosidase under
control of an HIV-1 LTR. Primary HIV-1 isolates (TCID50,
100–200) were incubated in triplicate with serial dilutions of
sera for 1 h at 37°C. Subsequently virus/serum mixtures were
added to the 96-well flat-bottom culture plate containing ad-
herent TZM-bl cells. Control consisted of cells plus virus (virus
control) and cells only (background control). Bioluminescence
was measured after 48 h using Bright Glo substrate solution per
the supplier’s protocol (Promega, Madison, WI). Neutralization
titers (NT50) are the dilutions at which relative light units
(RLUs) were reduced by 50% compared to those of virus con-
trol wells after subtraction of background RLUs.
Proliferation assay
The proliferation of mouse splenocytes was measured by 5-
bromo-2-deoxyuridine (BrdU) incorporation using a commer-
cial kit (Cell Proliferation ELISA, Roche Molecular Biochem-
icals, Mannheim, Germany). To assess antigen-specific
proliferation, cells (2  106 cell/ml) were incubated with and
without gp120BaL (5 g/ml), and as a positive control PHA-P
(2 g/ml, for 48 h, then pulsed with BrdU for 24 h). Cell pro-
liferation was measured according to the manufacturer’s in-
structions using a Spectra Max 340 ELISA Reader (Molecular
Devices, Sunnyvale, CA) at 370 nm and reference wavelength
of 492 nm.
Analysis of cytokine expression in vitro
Mouse splenocytes were seeded at 4  106 cells/ml (RPMI
1640, 2% FBS) and incubated with either gp120BaL, gp120SF162
(5 g/ml), or with V3 loop peptide (20 nM) for 72 h at 37°C.
Cell culture supernatants were harvested and analyzed for the
presence of cytokines. The cytokine assays were performed us-
ing Quantikine ELISA kits (R&D Systems, Inc., Minneapolis,
MN) according to the manufacturer’s instructions.
Statistical analysis
Statistical analysis of the results was preformed using
ANOVA, and Student’s t-test for the determination of the p
value.
RESULTS
Nasal immunization with recombinant HIV gp120
protein mixed with nanoemulsion induces anti-gp120
IgG antibodies in serum
BALB/c mice were intranasally immunized with either
gp120BaL or gp120SF162 serotypes to assess whether NE has ad-
juvant activity in mucosal immunization with recombinant
gp120 protein. Immunizations were carried out using 20 g of
gp120BaL in either saline or mixed with 0.1%, 0.5%, and 1%
NE concentrations. Blood samples collected at 6 weeks after
prime immunization (in animals boosted only at 3 weeks) and
at 12 weeks after prime immunization (in animals boosted at 3
and 6 weeks) were analyzed for gp120-specific antibodies by
ELISA. All mice immunized with either of the gp120BaL/NE
preparations were seropositive after only two immunizations
(Fig. 1). The anti-gp120BaL IgG response showed a concentra-
tion-dependent effect of NE, with the lowest titers in
gp120BaL/0.1% NE and highest in gp120BaL/1% NE immu-
nization groups (mean titers of 1.3  104 and 2.6  105, re-
spectively, Fig. 1A). In contrast, mice immunized with
gp120BaL in saline did not have detectable anti-gp120BaL anti-
bodies even after three immunizations. Serum anti-gp120 IgG


















































FIG. 1. Antibody response in mice intranasally vaccinated with two serotypes of recombinant gp120 and the nanoemulsion ad-
juvant. (A) Induction of serum anti-gp120BaL IgG in mice immunized with gp120BaL in 0.1%, 0.5%, and 1% NE. Anti-gp120BaL
blood samples collected at 6 weeks after prime immunization (in animals boosted only at 3 weeks) and at 12 weeks after prime
immunization (in animals boosted at 3 and 6 weeks) were analyzed for gp120-specific antibodies by ELISA. Intranasal (i.n.) and
intramuscular (i.m.) routes of immunization are indicated in the Figure. (B) Induction of anti-gp120SF162 IgG in mice i.n. im-
munized with two doses of gp120SF162 in 1% NE alone or with addition of CpG or MPL A. Anti-gp120 IgG antibodies were
measured at 6 weeks after prime immunization (in animals boosted at 3 weeks). Anti-gp120 antibody levels are presented as a
mean of endpoint titers ( SD) in serum of individual animals. Cross-reactivity of the anti-gp120 antibodies. Serum IgG from
mice immunized with either gp120BaL (C) or gp120SF162 (D) reacts with both gp120 serotypes. Data are presented as titration
curves of pooled serum from all immunized animals binding to either gp120SF162 or 120BaL. (E) Anti-gp120 IgG subclass pat-
tern in mice immunized i.n. with gp120/NE. The results are presented as a titer ratio of the specific subclass IgG to the overall
IgG titer.
A B
titers after intranasal immunization with either 0.5% or 1% NE
were comparable with the antibody response obtained after two
intramuscular injections with gp120BaL in saline or mixed with
1% NE, and the addition of a third intranasal immunization did
not significantly increase antibody titers (Fig. 1A). These re-
sults indicate that two intranasal gp120BaL/NE immunizations
produce a systemic immune response in mice.
Additional studies examining the NE immunizations were
carried out with a second gp120 serotype, gp120SF162. Simi-
larly to immunization with the gp120BaL, all mice immunized
with gp120SF162/NE responded with high anti-gp120SF162 IgG
titers. NE-produced immune responses were not enhanced 
significantly by the addition of unmethylated CpG ODN and
MPL A (Fig. 1B). To investigate the effect of combining the
NE with other immunostimulants, mice were immunized 
with the gp120SF162/NE with the addition of either CpG
(gp120SF162/NE  CpG) or MPL A (gp120SF162/NE  MPL
A). Combining NE with MPL A (but not with CpG) resulted
in a modest increase in mean antibody titer of 2- to 3-fold over
immunization with gp120SF162/NE alone; however, this differ-
ence was not statistically significant (p  0.05). In contrast,
nasal immunization with gp120SF162 antigen mixed with either
CpG or MPL A alone produced minimal immune responses
(Fig. 1B).
Intranasal immunization with either serotype of gp120 pro-
tein in NE produced cross-reacting IgG antibodies to the other
serotype (Fig. 1C and D). Serum IgG antibodies raised against
either gp120BaL or gp120SF162 reacted with the other serotype
with activity comparable to the immunizing envelope protein
and similar endpoint titers. This suggested that NE adjuvant
produced a repertoire of IgG capable of recognizing both vari-
able and conserved epitopes of the gp120 immunogen, which
could be of importance for protective immunity against differ-
ent serotypes of HIV-1.56 The subclass analysis of the anti-
gp120 IgG antibodies indicated a prevalence of IgG2b and
IgG2a over IgG1 antibodies, thus suggesting Th1 polarization
of the immune response in mice immunized with gp120/NE
(Fig. 1E). The absence of antibody response to intranasal. im-
munization with gp120 antigen alone did not allow for the de-
termination of IgG subclass without NE adjuvation.
Induction of secretory mucosal anti-gp120 IgA 
and IgG
BAL fluids, vaginal washes, and sera were analyzed for ev-
idence of mucosal response. Mice nasally immunized with
gp120SF162/NE had significant levels of gp120SF162-specific se-
cretory IgA and IgG antibodies in BAL fluid (Fig. 2A and B).
Similar to serum IgG, both mucosal IgA and IgG responses
demonstrate cross-reactivity with the gp120BaL immunogen.
Anti-gp120BaL IgA was also detected in the serum and impor-
tantly in secretions from distant (vaginal) mucosa after in-
tranasal NE immunization (Fig. 2C). In contrast, immunization
with either type of gp120 in saline failed to produce any type
of mucosal IgA and IgG response.
Cell-mediated immune responses
Cellular immune responses were assessed in vitro by anti-
gen-specific T cell proliferation and the pattern of cytokine pro-
duction. Antigen-specific proliferative responses were detected
only in splenic lymphocytes from animals immunized with the
gp120BaL/NE and were absent in either mice immunized with
either gp120BaL/saline or with control animals treated with
saline or NE alone (Fig. 3A). Intranasal immunization with
gp120BaL/NE also produced systemic, cross-reacting, cell-me-
diated immunity as demonstrated by significant interferon
(IFN)- production after in vitro stimulation with either
gp120BaL or gp120SF162 in cells harvested from animals im-
munized with gp120BaL (Fig. 3B). A substantial induction of
the IFN- was also obtained in these splenic cells with an
oligopeptide fragment of the V3 loop, thus indicating the pres-
ence of cells recognizing the dominant epitope associated with
virus binding and neutralization.9,57 In contrast, there was no
antigen-specific induction of interleukin (IL)-4 expression (not
shown), suggesting a Th1 polarization of the cellular immune
response. In addition, no significant cytokine response was
stimulated by gp120 in splenocytes from either control, non-
immune mice, or from mice immunized with gp120BaL in saline.
Immunization with gp120/NE induces antibodies that
neutralize HIV-1
To investigate the ability of gp120-specific antibodies in-
duced by NE nasal immunization to neutralize HIV, guinea pigs
were immunized with two doses of gp120SF162 in 1% NE. Im-
munization again produced significant levels of serum anti-
gp120 IgG antibodies in all animals (Fig. 4A) and as observed
with the murine immunizations the serum anti-gp120 IgG cross-
reacted with the gp120BaL immunogen. The immune sera from
guinea pigs were then tested for neutralizing activity against
HIV-1. The breadth of the neutralizing response was evaluated
using a panel of eight viruses, including three laboratory strains
and five primary HIV-1 isolates. Figure 4B documents that the
highest NT50 occurred in a single animal with the immunizing
serotype bearing M-tropic strain of HIVSF162 with an NT50 
225. Neutralizing activity was also present, albeit at lower lev-
els (NT50  50), in the two other animals immunized with this
antigen despite lower anti-gp120 IgG levels. Of interest, sig-
nificant neutralization was also observed with six of the seven
other HIV isolates (including all five primary isolates), with all
three guinea pigs generating an NT50 of at least 50 and ex-
ceeding 100 with two of the primary isolates (Fig. 4B). No neu-
tralization was observed with the laboratory strain of T-tropic
HIVMN virus.
DISCUSSION
Mucosal vaccines have the unique ability to induce both mu-
cosal and systemic immunity. This is potentially important in
the prevention of respiratory or sexually transmitted infections.
However, antigens delivered via mucosal routes are usually not
immunogenic and require adjuvants to enhance immunogenic-
ity.26,58–62 In this study we have demonstrated that intranasal
immunization with recombinant gp120 administered in a na-
noemulsion adjuvant induces potent systemic and mucosal im-
mune responses. In contrast to other mucosal HIV vaccines in
development, which reportedly require three or four immu-
nizations,41,59,60,62,63 the NE adjuvanted material produced high
titers of anti-gp120 antibodies after only two administrations.
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FIG. 2. Nasal immunization with gp120/NE induces mucosal IgA and IgG antibodies. Secretory anti-gp120 IgA (A) and IgG
(B) in bronchial lavage (BAL). The IgA and IgG antibodies recognize both autologous SF162 and heterologous BaL serotypes
as indicated. Assays were performed with undiluted and 1:10 diluted BAL fluids for IgA and IgG, respectively. (C) Anti-gp120
IgA in serum and in the vaginal washes of mice vaccinated with gp120BaL and NE adjuvant. Assays were performed with undi-
luted vaginal washes and with 1:50 diluted serum. Anti-gp120 IgA and IgG concentrations are presented as mean absorbance
(OD 405 nm  SD) obtained in ELISA. A statistically significant difference was observed between gp120/saline and all gp120/NE
groups (p 	 0.05), but no significant differences were observed in various NE concentrations (p  0.05).
In addition, serum IgG gp120 titers were comparable to those
reported for intramuscular immunization59,60 and those ob-
tained when we intramuscularly immunized mice (Fig. 1). The
response to NE-based nasal immunization also compared fa-
vorably with responses achieved through parenteral, bimodal
vaccine regiments of multiple DNA injections (three or four)
followed by subsequent boosts with recombinant antigen or ad-
enoviral vector.21,64,65
Nasal immunization with gp120/NE also induced significant
antigen-specific IgA and IgG antibodies in BAL fluid and vagi-
nal secretions. The IgA in these compartments may result from
local IgA production, which is supported by finding these an-
tibodies in both bronchial alveolar and vaginal mucosal secre-
tions. These results support the concept that nasal mucosa im-
munization can produce specific antibody responses in distant
mucosal sites.40,66–68 The presence of anti-HIV antibodies in
the genital tract could be useful in the prevention of HIV-1 in-
fection.2,69–71
A major goal in the design of the HIV vaccine is to gener-
ate high titers of antibodies that can neutralize many different
isolates of HIV.20 Multiple studies and clinical trials with
gp120-based vaccines document that despite high titers of anti-
gp120 antibodies there is often limited neutralizing activity
against naturally occurring HIV-1 isolates.6,56 Mucosal immu-
nization with gp120/NE induced highly cross-reactive IgG and
IgA antibodies against two diverse serotypes of gp120, BaL and
SF162, in both mice and guinea pigs. The relevance of this re-
sult was further illustrated in the HIV-1 neutralization analysis.
When tested for neutralizing activity against a panel of clade B
HIV-1 strains, sera from guinea pigs nasally immunized with
gp20SF162/NE demonstrated broad, neutralizing activity against
seven of eight strains and against all five primary HIV-1 iso-
lates. This included neutralization of the phylogenetically di-
verse clones BG1168.1, SS1196.11, QH0692.42, 3988.25, and
5768.4. These isolates were chosen because of their inclusion
in the recently proposed list of clade B HIV-1 clones for the
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FIG. 3. (A) Antigen-specific splenocyte proliferation. Splenocytes from animals immunized with gp120BaL were stimulated in
vitro with 2 g/ml of this anitgen. Cell proliferation was normalized to controls and presented as mean  SD of individual pro-
liferation indexes. The differences between the gp120BaL/saline and the gp120BaL/NE groups were all statistically significant (p 	
0.05). (B) Antigen-specific activation of cytokine production in splenocytes in vitro. Splenocytes from mice immunized with
gp120BaL were activated with 5 g/ml of either gp120BaL or gp120SF162, and with 20 nM of the V3 loop peptide. IFN- in cell
supernatants was determined by ELISA and concentrations are presented as the mean of individual samples  SD.
standardized assessment of vaccine-induced neutralizing anti-
bodies.54,72,73 Sequence and glycosylation site analysis indi-
cated a wide spectrum of genetic diversity, as expected for virus
strains obtained from independent infections. The reason for
this extensive cross-neutralization activity may involve stabi-
lization of the gp120 protein conformation, especially as a
trimer, by NE (data not shown). These data suggest a mucosal
vaccine consisting of multiple serotypes of recombinant HIV-
1 proteins and NE adjuvant could potentially produce even
broader-spectrum HIV-1 neutralizing activity.
Interestingly, no significant neutralizing activity was found
against another clade B laboratory strain––HIVMN. It is not
clear if this insensitivity may be related to the diversity of V3
loop epitope, which is linked to T-tropism of this viral isolate.74
In earlier studies and in vaccine trials, gp120MN and gp160MN
failed to produce neutralizing antibodies to the majority of HIV-
1 isolates,75,76 so there may be something uniquely nonim-
munogenic about this strain.
While NE nasal immunization induced potent systemic and
mucosal antibodies, it also induced significant cellular immune
responses, as documented by antigen-specific proliferation and
IFN- production in splenic lymphocytes. The induction of hall-
mark Th1 cytokine IFN- indicates activation of CD4 and
CD8 CTLs with both autologous gp120BaL and heterologous
gp120SF162 and with 35 aa V3 loop peptide.77,78 The pattern of
cytokine induction with significant INF- and absence of IL-4
suggests that NE alone can produce the Th1 polarization cel-
lular response.79 The cytokine data are supported by the anal-
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FIG. 4. (A) Nasal immunization of guinea pigs. Hartly guinea pigs (GP) were nasally vaccinated with 50 g gp120SF162 in 1%
NE then boosted i.n. with the same dose 3 weeks later. The serum IgG antibody response toward gp120SF162 and gp120BaL
serotypes was then measured at 6 weeks after initial immunization. Anti-gp120 IgGs are presented as OD 405 nm  SD obtained
in an ELISA using 1:200 dilutions of serum and either gp120SF162 or gp120BaL as the coating antigen. (B) Neutralizing antibody
produced by i.n. immunization with gp120SF162/NE. The neutralization of the laboratory strains and the primary isolates of HIV
was performed in the TZM-bl cell system. NT50 values represent the serum dilution at which relative luminescence units (RLU)
were reduced 50% compared to virus control. Individual preimmune sera from the same animals were used to determine back-
ground antiviral activity.
ysis of the anti-gp120 IgG isotype contribution to overall anti-
body response. A significant prevalence of IgG2 (b and a) over
IgG1 subclass antibodies clearly indicates a Th1 bias produced
by NE vaccination.80 In contrast, combining NE adjuvant with
adjuvants such as CpG or MPL A58,81 did not have a signifi-
cant effect on the response to immunization. The lack of CpG
effect could be due to a nonoptimized oligonucleotide sequence
and to the relatively low dose of CpG used in the study.21,82–84
The addition of MPL A resulted in only a minimal, nonsignif-
icant increase in serum antibody titers, which is in accordance
with the findings of VanCott et al.83 where intranasal immu-
nization was performed with gp160/liposome/MPL A. It is a
possibility that mixing MPL A with lipids can lower activity as
reported with liposome formulations.84 In any case, it appears
that this mucosal adjuvant activity is unique and requires the
presence of NE.
In summary, data presented in these studies illustrate that
nasal gp120/NE immunization produces a systemic and mu-
cosal antibody response with significant, cross-reactive neu-
tralizing immunity and a Th1 polarized CTL response. The mu-
cosal adjuvant capability could be helpful in the design of novel
HIV vaccines.
ACKNOWLEDGMENTS
The authors wish to express their thanks to Gloria Benko and
Donna Gauss for help in preparation of this manuscript. Sup-
port for these studies came from the Michigan Nanotechnology
Institute for Medicine and the Biological Sciences (M-NIMBS)
and the Ruth Dow Doan Endowment. Dr. D.M. Markovitz was
supported by the Burroughs Welcome Fund.
REFERENCES
1. Burton DR: A vaccine for HIV type 1: The antibody perspective.
Proc Natl Acad Sci USA 1997;94:10018–10023.
2. Burton DR, Desrosiers RC, Doms RW, et al.: HIV vaccine design and
the neutralizing antibody problem. Nat Immunol 2004;5:233–236.
3. Letvin NL: Progress and obstacles in the development of an AIDS
vaccine. Nat Rev Immunol 2006;6:930–939.
4. Srivastava IK, Stamatatos L, Legg H, et al.: Purification and char-
acterization of oligomeric envelope glycoprotein from a primary
R5 subtype B human immunodeficiency virus. J Virol 2002;76:
2835–2847.
5. Barnett SW, Lu S, Srivastava I, et al.: The ability of an oligomeric
human immunodeficiency virus type 1 (HIV-1) envelope antigen
to elicit neutralizing antibodies against primary HIV-1 isolates is
improved following partial deletion of the second hypervariable re-
gion. J Virol 2001;75:5526–5540.
6. Spearman P: Current progress in the development of HIV vaccines.
Curr Pharm Des 2006;12:1147–1167.
7. Cohen J: Public health: AIDS vaccine still alive as booster after
second failure in Thailand. Science 2003;302:1309a-1310.
8. McMichael AJ: HIV vaccines. Annu Rev Immunol 2006;24:
227–255.
9. Takahashi, Nakagawa Y, Pendleton CD, et al.: Induction of broadly
cross-reactive cytotoxic T cells recognizing an HIV-1 envelope de-
terminant. Science 1992;255:333–336.
10. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutral-
izing monoclonal antibodies of the IgG1 subtype protect against
mucosal simian-human immunodeficiency virus infection. Nat
Med 2000;6:200–206.
11. Betts MR, Nason MC, West SM, et al.: HIV nonprogressors pref-
erentially maintain highly functional HIV-specific CD8 T cells.
Blood 2006;107:4781–4789.
12. Grundner C, Li Y, Louder M, et al.: Analysis of the neutralizing
antibody response elicited in rabbits by repeated inoculation with
trimeric HIV-1 envelope glycoproteins. Virology 2005;331:33–46.
13. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellu-
lar immune responses with the initial control of viremia in primary
human immunodeficiency virus type 1 syndrome. J Virol 1994;
68:4650–4655.
14. Nabel GJ: Challenges and opportunities for development of an
AIDS vaccine. Nature 2001;410:1002–1007.
15. Ogg GS, Jin X, Bonhoeffer S, et al.: Quantitation of HIV-1-spe-
cific cytotoxic T lymphocytes and plasma load of viral RNA. Sci-
ence 1998;279:2103–2106.
16. Rosenberg ES, Altfeld M, Poon SH, et al.: Immune control of HIV-
1 after early treatment of acute infection. Nature 2000;407:
523–526.
17. Catanzaro AT, Koup RA, Roederer M, et al.: Phase 1 safety and
immunogenicity evaluation of a multiclade HIV-1 candidate vac-
cine delivered by a replication-defective recombinant adenovirus
vector. J Infect Dis 2006;194:1638–1649.
18. Graham BS, Koup RA, Roederer M, et al.: Phase 1 safety and im-
munogenicity evaluation of a multiclade HIV-1 DNA candidate
vaccine. J Infect Dis 2006;194:1650–1660.
19. Neutra MR and Kozlowski PA: Mucosal vaccines: The promise
and the challenge. Nat Rev Immunol 2006;6:148–158.
20. Pantaleo G and Koup RA: Correlates of immune protection in HIV-
1 infection: What we know, what we don’t know, what we should
know. Nat Med 2004;10:806–810.
21. Shu Y, Winfrey S, Yang Z-y, et al.: Efficient protein boosting af-
ter plasmid DNA or recombinant adenovirus immunization with
HIV-1 vaccine constructs. Vaccine 2007;25:1398–1408.
22. Goepfert PA, Horton H, McElrath MJ, et al.: High-dose recombi-
nant canarypox vaccine expressing HIV-1 protein, in seronegative
human subjects. J Infect Dis 2005;192:1249–1259.
23. Lu X, Wu S, Blackwell CE, Humphreys RE, von Hofe E, and Xu
M: Suppression of major histocompatibility complex class II-as-
sociated invariant chain enhances the potency of an HIV gp120
DNA vaccine. Immunology 2007;120:207–216.
24. Mazzoli S, Trabaironi D, Caputo SL, et al.: HIV-specific mucosal
and cellular immunity in HIV-seronegative partners of HIV-
seropositive individuals. Nat Med 1997;3:1250–1257.
25. Vajdy M, Singh M, Kazzaz J, et al.: Mucosal and systemic anti-
HIV responses in rhesus macaques following combinations of in-
tranasal and parenteral immunizations. AIDS Res Hum Retro-
viruses 2004;20:1269–1281.
26. Vajdy M, Srivastava I, Polo J, Donnelly J, O’Hagan D, and Singh
M: Mucosal adjuvants and delivery systems for protein-, DNA- and
RNA-based vaccines. Immunol Cell Biol 2004;82:617–627.
27. Balmelli C, Demotz S, Acha-Orbea H, De Grandi P, and Nardelli-
Haefliger D: Trachea, lung, and tracheobronchial lymph nodes are
the major sites where antigen-presenting cells are detected after
nasal vaccination of mice with human papillomavirus type 16 virus-
like particles. J Virol 2002;76:12596–12602.
28. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ,
Davis HL, and Rosenthal KL: Intranasal immunization with CpG
oligodeoxynucleotides as an adjuvant dramatically increases IgA
and protection against herpes simplex virus-2 in the genital tract.
J Immunol 2001;166:3451–3457.
29. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, and Kida H:
Intranasal immunization with formalin-inactivated virus vaccine in-
duces a broad spectrum of heterosubtypic immunity against in-
fluenza A virus infection in mice. Vaccine 2003;21:3212–3218.
POLARIZED RESPONSES AND NEUTRALIZING ANTIBODIES TO HIV-1 279
30. Yasuda Y, Isaka M, Taniguchi T, et al.: Frequent nasal adminis-
trations of recombinant cholera toxin B subunit (rCTB)-containing
tetanus and diphtheria toxoid vaccines induced antigen-specific
serum and mucosal immune responses in the presence of anti-rCTB
antibodies. Vaccine 2003;21:2954–2963.
31. Akagi T, Kawamura M, Ueno M, Hiraishi K, Adachi M, Serizawa
T, Akashi M, and Baba M: Mucosal immunization with inactivated
HIV-1-capturing nanospheres induces a significant HIV-1-specific
vaginal antibody response in mice. J Med Virol 2003;69:163–172.
32. Dumais N, Patrick A, Moss RB, Davis HL, and Rosenthal KL: Mu-
cosal immunization with inactivated human immunodeficiency
virus plus CpG oligodeoxynucleotides induces genital immune re-
sponses and protection against intravaginal challenge. J Infect Dis
2002;186:1098–1105.
33. Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal
challenge and prevention of AIDS by a multiprotein DNA/MVA
vaccine. Vaccine 2002;20:1949–1955.
34. Gherardi MM and Esteban M: Recombinant poxviruses as mucosal
vaccine vectors. J Gen Virol 2005;86:2925–2936.
35. Golding B, Eller N, Levy L, et al.: Mucosal immunity in mice im-
munized with HIV-1 peptide conjugated to Brucella abortus. Vac-
cine 2002;20:1445–1450.
36. Joseph J, Saubi N, Pezzat E, and Gatell JM: Progress towards an
HIV vaccine based on recombinant Bacillus Calamette-Guerin:
Failures and challenges. Expert Rev Vaccines 2006;5:827–
838.
37. Buonaguro L, Tornesello ML, Tagliamonte M, et al.: Baculovirus-
derived human immunodeficiency virus type 1 virus-like particles
activate dendritic cells and induce ex vivo T-cell responses. J Vi-
rol 2006;80:9134–9143.
38. Lundholm P, Leandersson A-C, Christensson B, Bratt G, Sand-
strom E, and Wahren B: DNA mucosal HIV vaccine in humans.
Virus Res 2002;82:141–145.
39. Singh M, Vajdy M, Gardner J, Briones M, and O’Hagan D: Mu-
cosal immunization with HIV-1 gag DNA on cationic microparti-
cles prolongs gene expression and enhances local and systemic im-
munity. Vaccine 2001;20:594–602.
40. Albu DI, Jones-Trower A, Woron AM, Stellrecht K, Broder CC,
and Metzger DW: Intranasal vaccination using interleukin-12 and
cholera toxin subunit B as adjuvants to enhance mucosal and sys-
temic immunity to human immunodeficiency virus type 1 glyco-
proteins. J Virol 2003;77:5589–5597.
41. Bradney CP, Sempowski GD, Liao H-X, Haynes BF, and Staats
HF: Cytokines as adjuvants for the induction of anti-human im-
munodeficiency virus peptide immunoglobulin G (IgG) and IgA
antibodies in serum and mucosal secretions after nasal immuniza-
tion. J Virol 2002;76:517–524.
42. Wu HY and Russell MW: Induction of mucosal immunity by in-
tranasal application of a streptococcal surface protein antigen with
the cholera toxin B subunit. Infect Immun 1993;61:314–322.
43. Donnelly S, Loscher CE, Lynch MA, and Mills KHG: Whole-cell
but not acellular pertussis vaccines induce convulsive activity in
mice: Evidence of a role for toxin-induced interleukin-1 beta in a
new murine model for analysis of neuronal side effects of vacci-
nation. Infect Immun 2001;69:4217–4223.
44. Mutsch M, Zhou W, Rhodes P, et al.: Use of the inactivated in-
tranasal influenza vaccine and the risk of Bell’s palsy in Switzer-
land. N Engl J Med 2004;350:896–903.
45. van Ginkel FW, Jackson RJ, Yuki Y, and McGhee JR: Cutting
edge: The mucosal adjuvant cholera toxin redirects vaccine pro-
teins into olfactory tissues. 2000;165:4778–4782.
46. Belyakov IM, Ahlers J, and Berzofsky JA: Mucosal AIDS vac-
cines: Current status and future. Expert Rev Vaccines 2004;3:
S65–73.
47. Eriksson K and Holmgren J: Recent advances in mucosal vaccines
and adjuvants. Curr Opin Immunol 2002;14:666–672.
48. Yuki Y and Kiyono H: New generation of mucosal adjuvants for
the induction of protective immunity. Rev Med Virol
2003;13:293–310. US Patent No. 6,015,832, 2000.
49. Hamouda T, Myc A, Donovan B, Shih AY, Reuter JD, and Baker
JRJ: A novel surfactant nanoemulsion with a unique non-irritant
topical antimicrobial activity against bacteria, enveloped viruses
and fungi. Microbiol Res 2001;156:1–7.
50. Myc A, Kukowska-Latallo JF, Bielinska AU, et al.: Development
of immune response that protects mice from viral pneumonitis af-
ter a single intranasal immunization with influenza A virus and na-
noemulsion. Vaccine 2003;21:3801–3814.
51. Bielinska AU, Janczak KW, Landers JJ, et al.: Mucosal immu-
nization with a novel nanoemulsion-based recombinant anthrax
protective antigen vaccine protects against Bacillus anthracis spore
challenge. Infect Immun 2007;75:4020–4029.
52. Moldoveanu Z, Love-Homan L, Huang WQ, and Krieg AM: CpG
DNA, a novel immune enhancer for systemic and mucosal immu-
nization with influenza virus. Vaccine 1998;16:1216–1224.
53. Li M, Gao F, Mascola JR, et al.: Human immunodeficiency virus
type 1 env clones from acute and early subtype B infections for
standardized assessments of vaccine-elicited neutralizing antibod-
ies. J Virol 2005;79:10108–10125.
54. Montefiori DC: Evaluating neutralizing antibodies against HIV,
SIV and SHIV in luciferase reporter gene assays. In: Current Pro-
tocols in Immunology (Coligan J, Kruisbeek A, Margulies D, She-
vach E, Strober W, and Coico R, eds.). John Wiley & Sons, New
York, 2004, pp. 12.11.11–12.11.15.
55. Mascola JR: Defining the protective antibody response to HIV-1.
Curr Mol Med 2003;3:209–216.
56. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hen-
drickson WA: Structure of an HIV gp120 envelope glycoprotein
in complex with the CD4 receptor and a neutralizing human anti-
body. Nature 1998;393:648–659.
57. Holmgren J and Czerkinsky C: Mucosal immunity and vaccines.
Nat Med 2005;11(4 Suppl.):S45–53.
58. O’Hagan DT, Ugozzoli M, Barackman J, et al.: Microparticles in
MF59, a potent adjuvant combination for a recombinant protein
vaccine against HIV-1. Vaccine 2000;18:1793–1801.
59. Vajdy M and Singh M: Intranasal delivery of vaccines against HIV.
Expert Opin Drug Deliv 2006;3:247–259.
60. Varona-Santos JT, Vazquez-Padron RI, and Moreno-Fierros L:
Production of a short recombinant C4V3 HIV-1 immunogen that
induces strong anti-HIV responses by systemic and mucosal routes
without the need of adjuvants. Viral Immunol 2006;19:237–249.
61. Buonaguro L, Racioppi L, Tornesello ML, et al.: Induction of neu-
tralizing antibodies and cytotoxic T lymphocytes in BALB/c mice
immunized with virus-like particles presenting a gp120 molecule
from a HIV-1 isolate of clade A. Antiviral Res 2002;54:189–201.
62. Mascola JR, Sambor A, Beaudry K, et al.: Neutralizing antibodies
elicited by immunization of monkeys with DNA plasmids and re-
combinant adenoviral vectors expressing human immunodefi-
ciency virus type 1 proteins. J Virol 2005;79:771–779.
63. Wu L, Kong W-p, and Nabel GJ: Enhanced breadth of CD4 T-cell
immunity by DNA prime and adenovirus boost immunization to
human immunodeficiency virus Env and Gag immunogens. J Vi-
rol 2005;79:8024–8031.
64. Holmgren J, Adamsson J, Anjuere F, et al.: Mucosal adjuvants and
anti-infection and anti-immunopathology vaccines based on
cholera toxin, cholera toxin B subunit and CpG DNA. Immunol
Lett 2005;97:181–188.
65. Johansson E-L, Wassen L, Holmgren J, Jertborn M, and Rudin A:
Nasal and vaginal vaccinations have differential effects on anti-
body responses in vaginal and cervical secretions in humans. In-
fect Immun 2001;69:7481–7486.
66. Kozlowski PA, Cu-Uvin S, Neutra MR, and Flanigan TP: Com-
parison of the oral, rectal, and vaginal immunization routes for in-
BIELINSKA ET AL.280
duction of antibodies in rectal and genital tract secretions of
women. Infect Immun 1997;65:1387–1394.
67. Johansson E-L, Rask C, Fredriksson M, Eriksson K, Czerkinsky
C, and Holmgren J: Antibodies and antibody-secreting cells in the
female genital tract after vaginal or intranasal immunization with
cholera toxin B subunit or conjugates. Infect Immun 1998;66:
514–520.
68. Mestecky J: Humoral immune responses to the human immuno-
deficiency virus type-1 (HIV-1) in the genital tract compared to
other mucosal sites. J Reprod Immunol 2006;72:1–17.
69. Russell MW and Mestecky J: Humoral immune responses to mi-
crobial infections in the genital tract. Microbes Infect 2002;4:
667–677.
70. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, and Wyatt R:
Characterization of antibody responses elicited by human immu-
nodeficiency virus type 1 primary isolate trimeric and monomeric
envelope glycoproteins in selected adjuvants. J Virol 2006;80:
1414–1426.
71. Mascola JR, D’Souza P, Gilbert P, et al.: Recommendations for
the design and use of standard virus panels to assess neutralizing
antibody responses elicited by candidate human immunodeficiency
virus type 1 vaccines. J Virol 2005;79:10103–10107.
72. Goodenow MM and Collman RG: HIV-1 coreceptor preference is
distinct from target cell tropism: A dual-parameter nomenclature
to define viral phenotypes. J Leukoc Biol 2006;80:965–972.
73. Gorse GJ, Corey L, Patel GB, et al.: HIV-1MN recombinant gly-
coprotein gp160 vaccine-induced cellular and humoral immunity
boosted with HIV-1MN recombinant glycoprotein120 vaccine. Na-
tional Institute of Allergy and Infectious Diseases AIDS Vaccine
Evaluation Group. AIDS Res Hum Retroviruses 1999;15:115–132.
74. Wrin T, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JH:
Adaptation to persistent growth in the H9 cell line renders a pri-
mary isolate of human immunodeficiency virus type 1 sensitive to
neutralization by vaccine sera. J Virol 1995;69:39–48.
75. Andrianov AM and Veresov VG: Determination of structurally
conservative amino acids of the HIV-1 protein gp120 V3 loop as
promising targets for drug design by protein engineering ap-
proaches. Biochemistry (Moscow) 2006;V71:906–914.
76. Carmichael A, Jin X, and Sissons P: Analysis of the human env-
specific cytotoxic T-lymphocyte (CTL) response in natural human
immunodeficiency virus type 1 infection: Low prevalence of
broadly cross-reactive env-specific CTL. J Virol 1996;70:
8468–8476.
77. Bradley LM, Dalton DK, and Croft M: A direct role for IFN-gamma
in regulation of Th1 cell development. J Immunol 1996;157:
1350–1358.
78. Mosmann TR: T lymphocyte subsets, cytokines, and effector func-
tions. Ann NY Acad Sci 1992;664:89–92.
79. Kornbluth RS and Stone GW: Immunostimulatory combinations:
Designing the next generation of vaccine adjuvants. J Leukoc Biol
2006;80:1084–1102.
80. Hartmann G, Weeratna RD, Ballas ZK, et al.: Delineation of a CpG
phosphorothioate oligodeoxynucleotide for activating primate im-
mune responses in vitro and in vivo. J Immunol 2000;164:
1617–1624.
81. Klinman DM, Xie H, and Ivins BE: CpG oligonucleotides improve
the protective immune response induced by the licensed anthrax
vaccine. Ann NY Acad Sci 2006;1082:137–150.
82. Kojima Y, Xin K-Q, Ooki T, et al.: Adjuvant effect of multi-CpG
motifs on an HIV-1 DNA vaccine. Vaccine 2002;20:2857–2865.
83. VanCott TC, Kaminski RW, Mascola JR, et al.: HIV-1 neutraliz-
ing antibodies in the genital and respiratory tracts of mice in-
tranasally immunized with oligomeric gp160. J Immunol
1998;160:2000–2012.
84. Greene S, Fortier A, Dijkstra J, et al.: Liposomal vaccines. Adv
Exp Med Biol 1995;383:83–92.
Address reprint request to:
James R. Baker, Jr.
University of Michigan-MNIMBS
1150 West Medical Center Drive
9220 MSRB III
Ann Arbor, Michigan 48109
E-mail: jbakerjr@umich.edu
POLARIZED RESPONSES AND NEUTRALIZING ANTIBODIES TO HIV-1 281
This article has been cited by:
1. Angelia Colwell Berkowitz, Diane M. Goddard. 2009. Novel Drug Delivery Systems. Journal of Neuroscience Nursing 41:2, 115-120.
[CrossRef]
